SANA AB Share Price

SANION

SE0005794617

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 03/07/2026 BST			5-day change	1st Jan Change
13.31 ^SEK	+4.80%		+2.38%	-37.22%

06-17	Saniona AB - Special Call
06-09	Calendar: Tuesday, June 9	FW

Last Transcript: SANA AB

Saniona AB - Special Call

06-17

More transcripts

Analysts' recommendations: SANA AB

05-28	Redeye raises fair value for Saniona to SEK 20 (19)	FW
11-26	Workday's Q3 Beat Highlights AI and Partner Momentum, RBC Says	MT
11-13	Affärsvärlden Issues Neutral Recommendation for Saniona	FW
25/09/25	Redeye Raises Target Price for Saniona to 19 SEK from 12 SEK	FW
25/09/25	Redeye Raises Target Value for Saniona to 19 Kronor (from 12)	FW

More recommendations

News in other languages: SANA AB

06-14	Syrien: Planen keine Beteiligung am Krieg im Libanon
06-08	Irak und Syrien öffnen Luftraum wieder
05-04	Syrien öffnet sich wieder für Visa und Mastercard
03-05	Nombre de morts, pays par pays, après l'attaque de l'Iran par les USA et Israël
02-04	Syrien lässt Öl- und Gasvorkommen vor Küste erkunden

More news

Managers and Directors: SANA AB

Manager	Title	Age	Since
Janus Schreiber Larsen COO	Chief Operating Officer	54	28/02/2025
Thomas Feldthus CEO	Chief Executive Officer	66	29/04/2022
Palle Christophersen CTO	Chief Tech/Sci/R&D Officer	68	31/12/2013

Director	Title	Age	Since
Jørgen Drejer CHM	Chairman	71	29/04/2022
Carl Johan Bertil Sundberg BRD	Director/Board Member	68	31/12/2014
Anna Ljung BRD	Director/Board Member	46	18/01/2018

More insiders

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-27 - Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
03/07/26	SEK 13.31	+4.80%	801,874
02/07/26	SEK 12.70	-1.70%	262,464
01/07/26	SEK 12.92	-1.45%	149,328
30/06/26	SEK 13.11	+1.39%	286,033
29/06/26	SEK 12.93	-0.54%	209,983

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Market Cap	1.84B 190M 167M 153M 143M 271M 18.14B 275M 714M 8.92B 715M 700M 30.72B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	1.84B 190M 167M 153M 143M 271M 18.14B 275M 714M 8.92B 715M 700M 30.72B	EV / Sales 2026 *	6.88x	EV / Sales 2027 *	4.74x
Free-Float	81.6%	Yield 2026 *	-	Yield 2027 *	-

06-17	Saniona AB - Special Call
06-09	Calendar: Tuesday, June 9	FW
06-08	Calendar Tuesday June 9	FW
05-28	Redeye raises fair value for Saniona to SEK 20 (19)	FW
05-27	Voleon Capital no longer a public short seller in Saniona	FW
05-27	Calendar Wednesday May 27	FW
05-26	Bonesupport tumbles in Stockholm, OMXS30 index down 0.9 percent	FW
05-26	Saniona AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-26	Saniona AB, Q1 2026 Earnings Call, May 26, 2026
05-26	Stockholm stocks slip in early Tuesday trading, Bonesupport raises U.S. outlook	FW
05-26	Stockholm Stock Exchange expected to open Tuesday with mixed trend	FW
05-26	Saniona Q1 revenue SEK 4.6 mln	RE
05-26	Saniona reports widening operating loss	FW

06-23	Saniona: Our take on the SAN2668 R&D day	AQ
06-11	Three shots on goal: Saniona prepares to enter the clinic	AQ
06-04	Saniona to Host Virtual R&D Day Focusing on SAN2668 for Severe Pediatric Epilepsies	AQ
05-28	Saniona (Q1 Review): Setting up for the long run	AQ
05-27	Bulletin from the Saniona AB annual shareholders’ meeting on May 27, 2026	AQ

1 day	+4.80%
1 week	+2.38%
Current month	+1.53%
1 month	-2.13%
3 months	-18.64%
6 months	-36.92%
Current year	-37.22%

1 week	12.7	13.83
1 month	12.25	13.83
Current year	12.25	28.3
1 year	8.03	28.3
3 years	1.74	28.3
5 years	1.57	28.3
10 years	1.57	55

SANA AB Share Price

Stocks

SANION

SE0005794617

Biotechnology & Medical Research

Valuation: SANA AB

Chart: SANA AB

Latest news : SANA AB

Last Transcript: SANA AB

Analysts' recommendations: SANA AB

Press Releases: SANA AB

News in other languages: SANA AB

Quotes and Performance

Course Extremes

Managers and Directors: SANA AB

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
12-28	Thomas Feldthus	Sell	Chief Executive Officer	5,000	0.0036%
12-28	Thomas Feldthus	Sell	Chief Executive Officer	5,000	0.0036%
12-28	Thomas Feldthus	Sell	Chief Executive Officer	5,000	0.0036%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SANA AB	+4.80%	+2.38%	+30.49%	+79.38%	190M
ARGENX SE	+0.68%	+5.92%	+77.86%	+139.22%	59.1B
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.26%	+91.40%	55.19B
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	24.67B
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+43.36%	-4.67%	19.69B
GENMAB A/S	-0.29%	+9.78%	+43.90%	-28.41%	17.56B
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+186.15%	+361.42%	16.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+37.85%	-	14.84B
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	14.04B
Average	+3.06%	+7.95%	+51.87%	+139.84%	24.57B
Weighted average by Cap.	+2.46%	+6.47%	+58.30%	+136.93%

	2026 *	2027 *
Net sales	267M 27.68M 24.2M 22.24M 20.73M 39.32M 2.64B 39.92M 104M 1.3B 104M 102M 4.46B	388M 40.21M 35.15M 32.3M 30.11M 57.11M 3.83B 57.98M 151M 1.88B 151M 148M 6.48B
Net income	-	-
Net Debt	-	-